Lantern Pharma Inc. (LTRN)
Lantern Pharma Statistics
Share Statistics
Lantern Pharma has 10.78M shares outstanding. The number of shares has increased by 0.24% in one year.
| Shares Outstanding | 10.78M |
| Shares Change (YoY) | 0.24% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 23.23% |
| Shares Floating | 8.03M |
| Failed to Deliver (FTD) Shares | 4.51K |
| FTD / Avg. Volume | 5.32% |
Short Selling Information
The latest short interest is 176.91K, so 1.64% of the outstanding shares have been sold short.
| Short Interest | 176.91K |
| Short % of Shares Out | 1.64% |
| Short % of Float | 2.2% |
| Short Ratio (days to cover) | 4.74 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -2.92. Lantern Pharma's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -2.92 |
| PS Ratio | 0 |
| Forward PS | 1.1 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Lantern Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.83, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.83 |
| Quick Ratio | 5.83 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-989.58M |
| Employee Count | 21 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -59.14% in the last 52 weeks. The beta is 1.63, so Lantern Pharma's price volatility has been higher than the market average.
| Beta | 1.63 |
| 52-Week Price Change | -59.14% |
| 50-Day Moving Average | 4.21 |
| 200-Day Moving Average | 3.92 |
| Relative Strength Index (RSI) | 38.53 |
| Average Volume (20 Days) | 84.72K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -22.22B |
| Net Income | -20.78B |
| EBITDA | -22.22B |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1930.92 |
Balance Sheet
The company has 7.51M in cash and 243.66M in debt, giving a net cash position of -236.15M.
| Cash & Cash Equivalents | 7.51M |
| Total Debt | 243.66M |
| Net Cash | -236.15M |
| Retained Earnings | -76.03B |
| Total Assets | 25.57M |
| Working Capital | 20.92M |
Cash Flow
In the last 12 months, operating cash flow was -17.81B and capital expenditures 0, giving a free cash flow of -17.81B.
| Operating Cash Flow | -17.81B |
| Capital Expenditures | 0 |
| Free Cash Flow | -17.81B |
| FCF Per Share | -1655.15 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LTRN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for LTRN is $25, which is 608.2% higher than the current price. The consensus rating is "Hold".
| Price Target | $25 |
| Price Target Difference | 608.2% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -1.17 |
| Piotroski F-Score | 2 |